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22 The Journal of Thoracic and Cardiobjective: Accurate preoperative staging is essential for the optimal management of
atients with lung cancer. An important goal of preoperative staging is to identify
ediastinal lymph node metastasis. Computed tomography and positron emission
omography may identify mediastinal lymph node metastasis with sufficient sensi-
ivity to allow omission of mediastinoscopy. This study utilizes our experience with
atients with clinical stage I lung cancer to perform a decision analysis addressing
hether mediastinoscopy should be performed in clinical stage I lung cancer
atients staged by computed tomography and positron emission tomography.
ethods: We retrospectively reviewed our thoracic surgery database for cases
etween May 1999 and May 2004. Patients deemed clinical stage I by computed
omography and positron emission tomography were chosen for further study.
ndividual computed tomography, positron emission tomography, and operative and
athology reports were reviewed. The postresection pathologic staging and long-
erm survival were recorded. A decision model was created using TreeAgePro
oftware and our observed data for the prevalence of mediastinal lymph node
etastases and for the rate of benign nodules. Data reported in the literature were
lso utilized to complete the decision analysis model. A sensitivity analysis of key
ariables was performed.
esults: A total of 248 patients with clinical stage I lung tumors were identified. One
undred seventy-eight patients (72%) underwent mediastinoscopy before resection,
nd 5/178 (3%) showed N2 disease. An additional 9 patients were found to have N2
etastasis in the final resected specimen, resulting in a total of 14/248 patients
5.6%) with occult mediastinal lymph node metastases. Benign nodules were found
n 19/248 (8%) of patients. Decision analysis determined that mediastinoscopy
dded 0.008 years of life expectancy at a cost of $250,989 per life-year gained. The
utcome was sensitive to the prevalence of N2 disease in the population and the
enefit of induction versus adjuvant therapy for N2 lung cancer. If the prevalence of
2 disease exceeds 10%, the sensitivity analysis predicts that mediastinoscopy
ould lengthen life at a cost of less than $100,000 per life-year gained.
onclusion: Patients with clinical stage I lung cancer staged by computed tomog-
aphy and positron emission tomography benefit little from mediastinoscopy. The
urvival advantage it confers is very small and is dependent on the prevalence of N2
etastasis and the unproven superiority of induction therapy over adjuvant therapy.
vascular Surgery ● April 2006
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G
TSatients with non–small cell lung cancer (NSCLC) are
typically offered surgical resection if they are felt to
have stage I or stage II disease after clinical staging.
he need to exclude N2 disease before thoracotomy is
enerally well accepted for clinical stage II NSCLC, but
here is less widespread agreement that this is necessary for
atients with clinical stage I disease. Many surgeons will
ccept the results of noninvasive methods for hilar and
ediastinal nodal staging, particularly with the widespread
ncorporation of positron emission tomography with F-18
uorodeoxyglucose (FDG-PET) into the staging armamen-
arium. Given the reported high sensitivity of FDG-PET for
odal metastasis and the expected low prevalence of occult
2 disease in patients who have N0 disease based on
omputed tomography (CT) and FDG-PET, many surgeons
re willing to skip the invasive staging and proceed directly
o thoracotomy.
One estimate of the prevalence of N2 disease in resect-
ble NSCLC comes from the data from van Tinteren and
olleagues, who reported the presence of N2 disease in 4/92
atients and N3 disease in 2/92 patients after clinical staging
o exclude nediastinal disease using CT and positron emis-
ion tomography (PET).1 Choi and colleagues reported a
eries of 291 patients with clinical stage I lung cancer.2
hey observed 20 (6.9%) positive mediastinoscopies for N2
isease and another 25 cases of N2 disease at thoracotomy.
he overall prevalence of N2 in that cohort was 15%
ithout the use of PET screening. Kim and colleagues
ocumented a 6.9% rate of occult N2 disease (negative
ediastinoscopy and positive N2 at thoracotomy) in a co-
ort of patients with predominantly clinical stage I disease
80% described as stage I). FDG-PET scanning was not
outinely used in this group, suggesting that routine use of
ET to define clinical stage I might decrease the prevalence
f N2 disease even further.3
Mediastinoscopy would theoretically benefit patients
ith N2 disease that was undetected by both PET and CT if
here were an alternative to surgery alone that improved
urvival (induction therapy) or if there were an additional
azard caused by thoracotomy that could be avoided by
nowing N2 status in advance of thoracotomy.4,5 It is dif-
cult to estimate the benefit or lack of benefit of preresec-
Abbreviations and Acronyms
CT  computed tomography
FDG-PET positron emission tomography with F-18
fluorodeoxyglucose
JCOG  Japan Clinical Oncology Group
NSCLC  non–small cell lung cancer
PET  positron emission tomographyion identification of the N2 disease for a patient with s
The Journal of Thoraciclinical stage I NSCLC and pathological stage IIIa NSCLC.
ecent reports have demonstrated a benefit of adjuvant
hemotherapy for selected patients with resected lung can-
er.6,7 It is arguable that for patients with minimal N2
isease, induction therapy and resection would hold similar
enefit as resection followed by adjuvant therapy.
On the other hand, a patient with a suspicious lung mass
hat turns out to be benign would not benefit from medias-
inoscopy. Patients without N2 disease (ie, the true nega-
ives, the pathological stage I and II patients) do not benefit
ither, and thus might be harmed as there is no benefit to
ounterbalance the risks. Given all these considerations, it
eems worthwhile to explore the value of mediastinoscopy
n the typical patient with known or suspected early stage
ung cancer to challenge whether routine mediastinoscopy is
arranted in such patients. Using the techniques of decision
nalysis with specially designed software, a trial can be
imulated to answer the question with existing data.
The primary objective of this article is to evaluate
hether mediastinoscopy with lymph node biopsies identi-
es mediastinal lymph node metastasis in patients judged to
ave clinical stage I NSCLC after CT and FDG-PET with
ufficient frequency to justify its routine use for these
atients.
ethods
decision analysis model was constructed using Tree Age Pro
005 software (release 2, TreeAge Software, Inc, Williamstown,
A). The criteria were chosen to define a population of patients
hat would be representative of common clinical findings in pa-
ients facing a routine pulmonary resection for suspected lung
ancer. This type of analysis is well described in the literature and
he interested reader can find detailed explanations elsewhere.8
here are specific examples of similar works that address topics of
nterest to the thoracic surgery community.9-11 Such analyses are
tructured to include a base strategy and an alternative strategy.
he results are reported as incremental cost-effectiveness: the ratio
f additional costs imposed by the alternative strategy over the
dditional benefits gained. When one strategy is shown to be both
ore effective and less expensive than the other strategy, it is said
o “dominate” the more expensive and less effective alternative.
Many of the results used to fuel the analysis came from our
wn clinical practice. A retrospective review was performed of the
utcomes of surgery in patients with clinical stage I lung cancer at
ur center for the 5-year period from May 1999 to April 2004. This
roject utilized data from an ongoing thoracic surgery database
hat is approved by the institutional review board and covered by
atient consent. Included patients were those with clinical stage I
nown or suspected NSCLC. Patients were excluded from the
nalysis if they underwent resection but did not have both FDG-
ET and CT scans preoperatively. Patients who were managed
onoperatively (ie, with neither mediastinoscopy nor resection)
ere also excluded. The combined results of mediastinoscopy and
ediastinal lymph node sampling were used to establish the prev-
lence of mediastinal metastasis in these patients. Both mediastinal
ampling and mediastinal dissection were used during this time
and Cardiovascular Surgery ● Volume 131, Number 4 823
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G
TSeriod as many of these patients were participants in a clinical trial
omparing these staging strategies. We used our data in the deci-
ion tree for the point estimates for the prevalence of N2 disease,
he prevalence of benign lesions, the sensitivity of mediastinos-
opy, the mortality after operation, and the rate of positive medi-
stinoscopy results.
Data were also obtained by literature search to provide an
stimate of costs of diagnostic and therapeutic intervention. The
nitial search strategy included use of Medline to search for works
ased on keywords “lung cancer” and “mediastinoscopy.” These
eferences were reviewed and were augmented with additional
itations from the lists of references within the works chosen for
loser scrutiny. The chosen references were then used to create
easonable estimates for the costs of the diagnostic and therapeutic
nterventions, the benefits accrued to the patients, and the proba-
ilities of certain key events that would occur to the patients
ubsequent to the decision of mediastinoscopy versus resection.
he specific point estimates were chosen from the range of re-
orted values as subjective best estimates by the authors, but a
iberal range of alternative values were included for the sensitivity
nalysis. The selected point estimates and the ranges of values
iscovered in the literature are reported in Table E1 along with the
Figure 1. Decision tree depicting the decision analysis
lung cancer patients. The figure depicts the event pro
non-use of routine mediastinoscopy in clinical stage I
described in the methods section of the text. The box in
for this analysis and these are reproduced in greatereferences that were used to make the estimates. 2
24 The Journal of Thoracic and Cardiovascular Surgery ● ApriIn keeping with the usual practice of decision analysis, a
ecision tree was constructed and loaded with the associated costs,
enefits, and probabilities. The tree is shown in Figure 1. The tree
eads from left to right and begins with a decision node (square) in
hich “no mediastinoscopy” is the base pathway and “mediasti-
oscopy” is the alternative pathway. From there, a series of prob-
bility nodes (circle) capture the likelihood of chance events in
atients subjected to either of the two pathways. Finally, the
erminal nodes (triangles) represent terminal states for the analysis
nd are labeled with the costs expended to reach that state as well
s the life expectancy of patients reaching that location on the flow
iagram. Once the model was run with the baseline assumptions
nd the initial estimates for probabilities, costs, and survivals, the
odel was then investigated with a sensitivity analysis. All vari-
bles were subjected to sensitivity testing and those demonstrating
nfluence on the resulting incremental cost-effectiveness estimates
ere reported. The perspective of the analysis is that of the payor
s we ignore other societal costs such as lost productivity by the
atient or lost productivity by caregivers providing direct support
o the patient. The time horizon for this study is 5 years from the
nset of therapy. Incremental costs and incremental survival dif-
erences beyond 5 years are assumed to be negligible between the
the routine use of mediastinoscopy in clinical stage I
ities, costs and outcomes associated with the use or
cancer patients. The symbols used in the diagram are
lower left of the figure records the assumptions made
l in electronic Table E1.for
babil
lung
the
detaistrategies.
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G
TSesults
n our center, from May 1999 to May 2004, there were 248
atients considered eligible for this analysis. Of these 248
atients, 178 (72%) underwent mediastinoscopy. Only
/178 patients (3%) had involvement of the mediastinal
ymph nodes detected by mediastinoscopy. One of these 5
atients underwent resection; the remaining 4 did not. De-
pite negative mediastinoscopy results, an additional 8 me-
iastinoscopy patients were found to have N2 mediastinal
etastases at the time of thoracotomy, leaving a total of
3/178 (7.3%) patients classified as N2 disease after all 3
taging procedures. The sensitivity of mediastinoscopy in
his population was therefore 5 of 13 (38%). Of the 70
atients for whom mediastinoscopy was omitted, 1 had N2
isease. Taken as a whole, the rate of N2 disease in the
ntire cohort is 14/248 (5.6%).
The mortality of thoracotomy in our patients was 1.6%
4/248). The final stage distribution of the entire cohort is
ecorded in Table 1. The 5-year survival of the entire
ohort of 248 patients is estimated to be 70.9% after a
edian follow-up of 30 months. The median survival for
he 14 patients found to have N2 disease is 36.1 months.
f the 19 patients with benign disease are excluded, the
29 cancer patients experienced 21 recurrences (9.2%) in
he first year of follow-up: 5 considered local, 8 regional,
ABLE 1. Pathological stage in 248 clinical stage I lung
umors
Pathological stage Number of patients (%)
T1N0 108 (43.5)
T2N0 71 (28.6)
T3N0 8 (3.2)
T4N0 3 (1.2)
T1N1 6 (2.4)
T2N1 11 (4.4)
T3N1 2 (0.8)
T1N2 4 (1.6)
T2N2 5 (2.0)
T4N2 1 (0.4)*
TXN2 4 (1.6)†
T1NX 4 (1.6)
T4NX 2 (0.8)
Benign nodule 19 (7.7)
Includes 1 positive mediastinoscopy, resected anyway. †Includes 4 pos-
tive mediastinoscopy, no resection.
ABLE 2. Result of decision analysis base case
trategy Cost ($) Incremental cost (%)
o mediastinoscopy 14,764
ediastinoscopy 16,804 2041CER, Incremental cost-effectiveness ratio in dollars per life-year.
The Journal of Thoracicdistant, and 1 uncertain in location. The 5-year pro-
ression-free survival in the 229 patients with cancer is
stimated to be 73%. There was no difference in the
-year progression-free survival between the 169 cancer
atients who had mediastinoscopy (72%) and the 60 who
id not (77%; P  .245).
Additional data to bolster this analysis were kindly sup-
lied by Dr. Rosalie Viney on behalf of her coinvestigators
n the Centre for Health Economics Research and Evalua-
ion, University of Technology, Sydney, Australia. These
ata were acquired in a prospective, randomized trial of
ET in the management of clinical stage I and stage II lung
ancer but the specific parameters were not able to be
educed from the article alone.12 In that trial, 183 patients
ere enrolled and 42 of them were in stage I after both CT
nd PET. Of the 12/42 patients clinically staged T1N0, 1
as found to be benign, 10 were pathologically staged
1N0, and 1 was found to be T1N1 after resection. Of the
0/42 patients clinically staged T2N0, 25 were T2N0, 3
ere T2N1, and 2 were T2N2. The overall prevalence of N2
isease in patients with clinical stage I disease after PET
nd CT screening was 2/42 (4.8%).
The results of the base case of the economic analysis are
hown in Table 2. This shows that the strategy to employ
ediastinoscopy routinely results in an estimated increase
n survival of 0.008 years and, as a result, the cost per
ife-year gained is $250,989.
ensitivity Analysis
he sensitivity analysis was conducted in several ways.
ll variables in the model were screened to identify
nfluential variables that most heavily impact the esti-
ated costs or survival durations of patients in either arm
f the decision tree. Table E2 demonstrates the impact of
he survival benefit of induction therapy versus postop-
rative adjuvant therapy on the incremental cost-effec-
iveness of mediastinoscopy. In a 1-way sensitivity anal-
sis, shown in Figure E1, the impact of the prevalence of
2 disease on the incremental cost-effectiveness of the
taging strategy is assessed. Finally, Table E3 contains a
-way sensitivity analysis that analyzes the 2 important
ariables simultaneously: the prevalence of N2 disease in
he population of interest and the benefit of induction
herapy over adjuvant therapy for those specific patients.
ffectiveness (y) Incremental effectiveness (y) ICER
7.307
7.315 0.008 250,989Eand Cardiovascular Surgery ● Volume 131, Number 4 825
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G
TSiscussion
his analysis has determined that routine mediastinoscopy
n patients judged to have clinical stage I NSCLC based on
oth CT and FDG-PET is an expensive diagnostic proce-
ure that adds very little to the life expectancy of the typical
atient. Depending on the willingness to pay of society or of
specific payer, this high cost per life-year gained may
ndicate that the routine use of mediastinoscopy could be
mitted.
The sensitivity of mediastinoscopy is lower in these
articular patients than is reported in many other studies of
ediastinoscopy. This is consistent with a phenomenon
emonstrated by Gould and colleagues who evaluated the
onditional performance of FDG-PET in the setting of var-
ous outcomes of an accompanying CT scan. Given a pre-
ious negative test, an additional screening test is likely to
ave lower sensitivity and higher specificity than that same
est would have in an unscreened population.14 Therefore, it
s not surprising that after a negative CT and FDG-PET,
ediastinoscopy demonstrates lower sensitivity and higher
pecificity than has been reported previously in less thor-
ughly screened populations.
It is notable that only 1 of the patients in our cohort who
id not have a mediastinoscopy was subsequently shown to
ave mediastinal metastases. The low rate of N2 disease in
ur own patients for whom mediastinoscopy was skipped
aises the concern that there was bias in the application of
ediastinoscopy. If there was no bias in the application of
ediastinoscopy, one would expect 5.6% prevalence of N2
n both groups: mediastinoscopy and no mediastinoscopy.
n fact the rates were 13/178 (7.3%) in the mediastinoscopy
roup and 1/70 (1.4%) in the no mediastinoscopy group.
he rates of benign lesions were 9/178 (5.1%) in the me-
iastinoscopy group and 10/70 (14.3%) in the no mediasti-
oscopy group. The differences in the rates of N2 disease
nd benign tumors suggest the existence of additional low-
isk criteria that led to the selection of the no mediastinos-
opy strategy. For the purposes of this article, however, the
alue of interest is the overall prevalence of 5.6%, as the
uestion at hand is whether routine use of mediastinoscopy
n all patients with clinical stage I NSCLC is justified.
The N2 patients in either arm of this decision analysis are
atients with minimal N2 burden, as demonstrated by their
egative CT and negative PET. As a result, the survival
stimates from the literature for patients with N2 disease,
hich will be largely based on cohorts with CT-positive
nd/or PET-positive mediastinal disease, are likely to be
orse than one might expect for the favorable group of
atients considered in this study. A reasonable estimate of
ife expectancy after a pulmonary resection that demon-
trates N2 disease can be obtained from the Japan Clinical
ncology Group (JCOG) study reported in 2004. Thesenvestigators randomized 119 patients with N2 disease after s
26 The Journal of Thoracic and Cardiovascular Surgery ● Apriomplete resection to receive or not to receive adjuvant
hemotherapy. The median survival was 36 months for both
roups. Given that the JCOG study included patients with
ore advanced disease than our patients with clinical stage
disease, it is likely that the N2 patients in the current study
ould do as well or better. Keller and colleagues reported a
ubgroup of 172 patients with single station N2 disease who
ad adjuvant therapy and experienced a median survival of
5 months.15 There are no substantial published studies that
llow for estimation of outcomes of patients with clinical
tage I but pathological stage IIIa disease who are given
nduction therapy before resection.
One limitation of this analysis is the fact that no adjust-
ent has been made for quality of life by using “utility”
stimations for each of the terminal states of the analysis. In
art this has been done by necessity: there are no good
stimates for utility in patients with NSCLC after surgery,
ailed induction therapy, or postoperative adjuvant therapy.
t is reasonable to assume that the average utility in either
rm would be the same. There are no major differences in
he anticipated morbidity or potential for disability between
he mediastinoscopy and the no mediastinoscopy arms of
his analysis. The mediastinoscopy procedure itself carries
ittle risk of discomfort or debilitating consequences. The
nly impact of the omission of utilities would be the dif-
erence between the cost per life-year gained versus the cost
er quality-adjusted life-year gained. If good estimates for
tility were available, adjusting the survival of patients with
SCLC for utility would likely result in a reduction of the
urvival estimates by about 30% as one converts life-year to
uality-adjusted life-year. In this manner, costs per quality-
djusted life-year would be higher than costs per life-year
y a factor equal to the reciprocal of the utility of the
verage lung cancer survivor. If the utility of these survivors
s 0.7, the cost per quality-adjusted life-year would be 1/0.7
r 1.4 times the cost per life-year gained. In the base case
his would be $358,555 per quality-adjusted life-year, thus
aking routine mediastinoscopy appear even less attractive.
These findings may be of little surprise to many surgeons
ho have already omitted mediastinoscopy from the routine
taging of their patients with clinical stage I disease. On the
ther hand, many surgeons who have been routinely em-
loying mediastinoscopy on all patients prior to thoracot-
my may have failed to adapt their inclusion criteria for
ediastinoscopy to reflect the additional information that
ET offers. For them, this analysis might provide an impe-
us to reevaluate their current staging strategy.
It should be noted that this study cannot address when to
se a PET scan. Other studies have looked at the incremental
ffectiveness and the incremental cost-effectiveness of PET
can conditional on CT scan showing operable lung cancer, but
uch studies have not looked at the specific subset of clinical
tage I lung cancer.16,17 Future work may be needed to clarify
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G
TShe order and relative importance of the many options available
o the thoracic surgeon for staging patients with known or
uspected lung cancer. Also, this study does not challenge the
eed to fully assess mediastinal lymph nodes in clinical stage
NSCLC. It is clear that mediastinal staging should be done in
ll patients, but it may be that the best time to do it for some
s at the time of the resection.
onclusion
he addition of mediastinoscopy to the routine evaluation of
otential surgical candidates with known or suspected stage
lung cancer is of questionable value given the high cost per
ife-year gained by that strategy. Clearer estimates of the
ost-effectiveness of such a strategy will be obtained by
athering stage-specific estimates of both the sensitivity of
ediastinoscopy in detecting N2 disease and the specificity
f FDG-PET and CT together to exclude it. Additional data
o be sought in future efforts in this field should include
urvival estimates in the unique subset of N2 patients who
ave no evidence for nodal metastasis by CT or FDG-PET
ut are found to have N2 disease either at the time of
horacotomy or at the time of a screening mediastinoscopy.
inally, the use of actual cost data in patients who meet the
riteria for inclusion into this study would also strengthen
he arguments offered in our analysis.
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r Cameron D. Wright (Boston, Massachusetts). Dr. Meyers and
olleagues are to be congratulated on presenting this thoughtful
tudy on the questionable benefits of mediastinoscopy in clinical
tage I NSCLC. On the one hand, I think Dr Meyers is already
reaching to the choir, as I believe the majority of US surgeons go
traight to resection if the patient is clinical stage I based on CT or
ET. I think this decision was based on old-fashioned clinical deci-
ion making, knowing the low prevalence of occult N2 disease, the
ifficulty and nuisance of performing mediastinoscopy, the question-
ble benefit of induction therapy, and the expected favorable survival
f occult N2 disease patients. Now, Dr Meyers and colleagues have
upported this practice pattern, if you will, with a decision analysis
odel that confirms the very low yield of occult N2 disease in patients
ith clinical stage I disease, which importantly highlights the surpris-
ngly high cost of routine mediastinoscopy from a public health
erspective. This is a timely report in this new era of evidence-based
edicine where the best available clinical evidence is marshaled to
upport a particular process of care. It is strengthened by an economic
nalysis that emphasizes just how expensive a simple diagnostic
urgical procedure can be and should give us pause as we spend our
aluable and limited health care resources on our patients. I believe
his well-done analysis indicates that routine mediastinoscopy in clin-
cal T1 tumors is clinically unproductive and excessively costly. I do,
owever, have some concerns about generalizing this conclusion to all
2 tumors. We all know that prevalence of N2 disease increases with
umor size. Indeed, Dr Meyers has reconfirmed that fact with his data,
ith T1 tumors having a prevalence of about 3% of N2 disease and
2 tumors having a prevalence of close to 10%. In the 2 cited PET
rials from his article, the incidence in a prospective fashion of N2
isease was 0% and 14% in T1 tumors and 7% and 20% in T2 tumors.
veraging this data together would suggest about 12% of clinical T2
umors are N2. This prevalence then potentially comes close to being
ost-effective in his model if the benefit of induction therapy is much
reater than one half a year based on a 2-way sensitivity analysis. This
s where the art of medicine comes in, I believe, as I do not think we
ave truly firm data about the value of induction therapy and its
omparison with adjuvant therapy. Dr Meyers, how confident are you
n the applicability of your conclusions to all T2 tumors within this
linical stage I group, and if presented next week with a patient with
7-cm T2, right upper lobe, biopsy-proven adenocarcinoma with a
egative CT PET, would you perform mediastinoscopy? I congratu-
ate Dr Meyers and his coauthors on an excellent presentation and for
larifying difficult clinical decisions in a rigorous scientific way.
Dr Meyers. Thanks for the comments and the questions. Cer-
ainly there have been many articles that suggest that there is a
ifference between T1 and T2 patients, and I would agree. My
onfidence in the upper end of T2 is not strong, and I think that that
ould be a particular group of patients where additional recruit-
ent or a prospective trial might be beneficial. If I were faced with
he 7-cm tumor that you described, I would do a mediastinoscopy,
ut I have equipoise with smaller T2 tumors, and I certainly think
hat that issue would be a good subject for an eventual clinical trial
o evaluate this strategy.
Dr Frank Detterbeck (Chapel Hill, North Carolina). There is
lot of data based on the CT literature that an adenocarcinoma or
central tumor has a very high false-negative rate, about a 20%hance of finding positive nodes. The PET literature really has not
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TSooked at the differences between adeno versus squamous or
entral versus peripheral. Have you looked at that in this model or
n your patient series, and if you haven’t, I wonder if you should.
think that the differences between these categories is larger than
he difference between T1 versus T2 in the CT literature.
Dr Meyers. Actually we have not looked at adenocarcinoma
ersus other subtypes or central tumors versus peripheral tumors.
hat we were trying to challenge was the notion of routine
ediastinoscopy for all patients. Therefore, we looked at all of the
1-T2 patients or stage I patients as a whole. Certainly with more
atients you would have more ability to parse out subgroups. Such
focus would take more patients than one center can provide.
Dr Robert J. Korst (New York, New York). I also enjoyed that
alk. My question again revolves around the assumptions made in any
ecision analysis model, and obviously the model is really only as
ood as the assumptions that are made. What I liked about this article
as that it was based on a lot of hard data and not that many
ssumptions were made. However, 1 assumption that is at the crux of
his model is that the detection of CT occult and PET occult disease,
r essentially micrometastatic mediastinal disease picked up by me-
iastinoscopy, improves survival by means of induction therapy.
lthough historical data suggest that mediastinoscopy-positive N2
isease carries a poor prognosis compared with mediastinoscopy-
egative N2 disease, these data may not apply when both CT as well
s PET are negative in the mediastinum. I guess that boils down to the
ole of induction therapy for occult micrometastatic disease in the
ediastinum. Many patients are long-term survivors after surgical
esection alone for such occult mediastinal disease, compared with
hose with radiographically obvious disease. I wanted to know where
ou got the numbers to put into your model to answer that question,
pecifically, where the data came from for patients with occult disease
ho just go to surgery.
Dr Meyers. Well, in order to challenge the conventional wisdom
f performing mediastinoscopy in all patients, I had to make the same
ssumptions that are needed to support the conventional wisdom. You
ould have to assume superiority of induction over adjuvant to even
ake an argument about this topic or simply to have this discussion.
here are no good data from which to make a true assessment of theThe Journal of Thoraciccenario I estimated the induction strategy would offer a 6-month
urvival advantage over the adjuvant therapy strategy, but as you
emember from my oral presentation, I allowed that there might be no
enefit, in which case there is no support for mediastinoscopy in those
atients whatsoever.
Dr Korst. Exactly, because there will absolutely be no benefit
f induction therapy does not improve survival in patients with
uch minimal disease in the mediastinum.
Dr Meyers. Right. We agree.
Dr Benedict Daly (Boston, Massachusetts). Bryan, I just have
quick comment. Most of us recognize the clear difference be-
ween stage Ia and stage Ib lung cancers, but I think that there is
lso a significant difference between peripheral and central clinical
tage I lung cancers. Even if you just look at stage Ia lung cancers,
or example, the incidence of unsuspected mediastinal lymph node
etastases in that small subset of patients with central tumors is
lmost 16 times greater than it is for patients with peripheral
umors. Do you really think that your conclusions apply to patients
ith central tumors?
Dr Meyers. Well, I base my conclusions on our global assess-
ent of stage I lung cancer patients in our experience, and I do not
hink that we have statistical power with the small number of
ccult N2 cases that we detected to really parse it into T1a and
1b. I share the suspicion of an increased risk of occult N2 disease
n the T2 patients. But still, you would have to go back to what Dr
orst said in his discussion: unless you know that there is a benefit
o induction over adjuvant, then the knowledge that you would
ain by doing a routine mediastinoscopy in a 7-cm T1b patient is
ot enough to merit mediastinoscopy.
Dr Daly. No, I am really talking about a patient with a 2.5-cm
entral tumor and a negative CT scan.
Dr Meyers. Right. If you have a positive mediastinoscopy,
hat is your action? If you skip the mediastinoscopy and find a
ingle N2 at thoracotomy, what is your reaction? What is the
ifference in the outcomes between those 2 scenarios? You have to
onsider the whole downstream decision making together. One
annot just pick 1 bit of the data and criticize it; you have to look
t the whole strategy, and when we do that, I think that it is stilltate of the art regarding benefit of induction therapy. In my baseline difficult to justify routine mediastinoscopy in the T2 patients.
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TSFigure E1. One-way sensitivity analysis based on the sensitivity of mediastinoscopy.
ABLE E1. Values for variables used in decision model
Est Range Refs
ost of item ($)
Induction chemotherapy 4200 3600-5000 18,19
Induction death 36,787 25,000-48,574 20,21
Negative med 2000 1500-3000 22-25
Positive med 4490 3500-5500 22-25
Resection benign mass 8900 7100-10,700 22
Resection malignant mass 14,214 13,178-14,800 22
Surgical postoperative death 36,787 25,000-48,574 22
urvival (y)
Healthy people age 66 18 15-22 26,27
Induction and surgery 2.5 1.5-3 10,20,21,28,29
Resection with pN0 7 5.0-10 30-32
Resection with pN1 4.5 3.0-5.5 33,34
Resection pN2, adjuvant 3 1.6-3 10,15,20,21,34-37,*
Survival benefit of induction 0.5 0.1-2.0 20,21
robabilities
Prevalence of N2 0.056 0.04-0.12 1,12,13,17,38-40,*
Benign lesion in lung 0.08 0.01-0.3 23,38,*
Death during induction 0.02 0-0.05 28,41,42
Progression during induction 0.1 0.05-0.2 28,41,42
Sensitivity of med 0.37 0.03-0.06 4,23,43-45,*
N2 resection after mediastinoscopy 0.04 Dependent on sens and prevalence
Death after operation 0.02 0.01-0.05 30,36,42,46-48,*
Death after induction  surgery 0.04 0.01-0.06 20,21,29,42,49,50
Positive mediastinoscopy 0.02 Dependent on sensitivity and prevalenceed, Mediastinoscopy; sens, *Values for which the current report serves as reference source.
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SABLE E2. One-way sensitivity analysis based on benefit of induction therapy versus adjuvant therapy in the
escribed cohort
nduction benefit (y) Strategy Cost (%) Incremental cost Effectiveness (y) Incremental effectiveness (y) ICER
.10 No
Med
14,764 7.31
Med 16,804 2041 7.31 0.00 1,548,382
.42 No
Med
14,764 7.31
Med 16,804 2041 7.31 0.01 304,068
.73 No
Med
14,764 7.31
Med 16,804 2041 7.32 0.01 168,587
.05 No
Med
14,764 7.31
Med 16,804 2041 7.32 0.02 116,624
.37 No
Med
14,764 7.31
Med 16,804 2041 7.33 0.02 89,147
.68 No
Med
14,764 7.31
Med 16,804 2041 7.34 0.03 72,148
.00 No
Med
14,764 7.31
Med 16,804 2041 7.34 0.03 60,594CER, Incremental cost effectiveness ratio in dollars per life-year gained; med, mediastinoscopy. G
TABLE E3. Two-way sensitivity analysis of incremental cost-effectiveness (cost per life-year gained) of routine medias-
inoscopy: impact of the prevalence of N2 disease and the benefit of induction therapy over adjuvant therapy
ncr surv induction > 0.1 0.417 0.733 1.05 1.367 1.683 2
rev of N2
0.12 213,094 97,565 63,266 46,810 37,147 30,791 26,293
0.107 280,379 117,316 74,177 54,235 42,743 35,270 30,021
0.093 386,307 144,033 88,522 63,894 49,987 41,053 34,827
0.08 568,491 181,630 108,075 76,923 59,713 48,795 41,253
0.067 926,143 237,250 136,042 95,366 73,413 59,677 50,270
0.053 1,809,083 325,537 178,845 123,297 94,073 76,050 63,823
0.04 5,591,276 481,412 251,566 170,271 128,686 103,421 86,452
olumns indicate assumed benefit, measured in years of survival, after induction therapy versus adjuvant therapy for N2 disease. Rows indicate assumed
revalence of N2 disease in the population studied. Shaded cells in the upper right indicate combinations of survival estimates that yield incremental
ost-effectiveness ratios of less than $50,000 per life-year gained. Unshaded cells are combinations in which the mediastinoscopy strategy yields an
ncremental cost effectiveness ratio in dollars per life-year gained; med, mediastinoscopy (ICER) between $50,000 and $100,000 per life-year. Shaded cells
n the lower left indicate combinations that result in ICER greater than $100,000 per life-year gained.
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